Membrane receptor for thyroid hormone: Physiologic and pharmacologic implications

Annual Review of Pharmacology and Toxicology

Volumn 51, Issue , 2011, Pages 99-115

  Davis, Paul J ^a,b,c   Davis, Faith B ^a   Mousa, Shaker A ^c   Luidens, Mary K ^a,b   Lin, Hung Yun ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

angiogenesis; cancer cell proliferation; growth factors; integrin v 3; ion transport; nanoparticulate tetrac; protein trafficking; tetrac

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CETUXIMAB; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; LEVOTHYROXINE; LIOTHYRONINE; NANOPARTICLE; SODIUM PROTON EXCHANGE PROTEIN; TETRAIODOTHYROACETIC ACID; THYROID HORMONE RECEPTOR; THYRONINE; THYROXINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE CELL; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; DOWN REGULATION; DRUG FORMULATION; DRUG SENSITIVITY; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HORMONE STRUCTURE; HUMAN; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; KIDNEY CANCER; LUNG CANCER; NERVE FUNCTION; NONHUMAN; OSTEOCLASTOGENESIS; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIZATION; RETINOPATHY; THROMBOCYTE FUNCTION; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; INTEGRIN ALPHAVBETA3; NANOPARTICLES; NEOPLASMS; SIGNAL TRANSDUCTION; THYROXINE; TRIIODOTHYRONINE;

EID: 79951978814     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100512     Document Type: Article

References (71)

1. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, et al. 2005. Integrin ocv|33 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864-71 (Pubitemid 41002793)
2. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. 2005. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J. Cardiovasc. Pharmacol. 46:356-60 (Pubitemid 41262839)
3. Mousa SA, O'Connor L, Davis FB, Davis PJ. 2006. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147:1602-7
4. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. 2004. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145:3265-72 (Pubitemid 38829999)
5. Lin HY, Tang HY, Shih A, Keating T, Cao G, et al. 2007. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72:180-87 (Pubitemid 46273502)
6. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, et al. 2009. L-thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am. J. Physiol. Cell Physiol. 296:C980-91
7. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. 2000. Ligand binding to integrins. J. Biol. Chem. 275:21785-88 (Pubitemid 30621742)
8. Farwell AP, Tranter MP, Leonard JL. 1995. Thyroxine-dependent regulation of integrin-laminin interactions in astrocytes. Endocrinology 136:3909-15
9. Hoffman SJ, Vasko-Moser J, Miller WH, Lark MW, Gowen M, Stroup G. 2002. Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist. J. Pharmacol. Exp. Ther. 302:205-11 (Pubitemid 34680439)
10. Cheng SY, Leonard JL, Davis PJ. 2010. Molecular aspects of thyroid hormone actions. Endocr. Rev. 31:139-70
11. Yen PM, Ando S, Feng X, Liu Y, Maruvada P, Xia X. 2006. Thyroid hormone action at the cellular, genomic and target gene levels. Mol. Cell. Endocrinol. 246:121-27 (Pubitemid 43238405)
12. Moeller LC, Cao X, Dumitrescu AM, Seo H, Refetoff S. 2006. Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor |3 through the phosphatidylinositol 3-kinase pathway. Nucl. Recept. Signal. 4:e020
13. Lei J, Mariash CN, Bhargava M, Wattenberg EV, Ingbar DH. 2008. T3 increases Na-K-ATPase activity via a MAPK/ERK1/2-dependent pathway in rat adult alveolar epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 294:L749-54 (Pubitemid 351520108)
14. Davis PJ, Zhou M, Davis FB, Lansing L, Mousa SA, Lin HY. 2010. Mini-review: cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells. Physiol. Behav. 99:237-39
15. Incerpi S, Fiore AM, De Vito P, Pedersen JZ. 2007. Involvement of plasma membrane redox systems in hormone action. J. Pharm. Pharmacol. 59:1711-20 (Pubitemid 350221815)
16. Cao HJ, Lin HY, Luidens MK, Davis FB, Davis PJ. 2009. Cytoplasm-to-nucleus shuttling of thyroid hormone receptor-131 (TR|31) is directed from a plasma membrane integrin receptor by thyroid hormone. Endocr. Res. 34:31-42
17. Carter WJ, van der Weijden Benjamin WS, Faas FH. 1984. Effect of a protein-free diet on muscle protein turnover and nitrogen conservation in euthyroid and hyperthyroid rats. Biochem. J. 217:471-76 (Pubitemid 14178977)
18. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, et al. 2008. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr. Rev. 29:898-938
19. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, et al. 2004. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ. Res. 94:1500-6 (Pubitemid 38780323)
20. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, et al. 2008. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11:183-90
21. Lin HY, Davis PJ, Tang HY, Mousa SA, Luidens MK, et al. 2009. The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle 8:1877-82
22. Mousa SS, Davis FB, Davis PJ, Mousa SA. 2010. Human platelet aggregation and degranulation is induced in vitro by L-thyroxine, but not by 3,5,3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA). Clin. Appl. Thromb. Hemost. 16(3):288-93
23. Lin HY, Martino LJ, Wilcox BD, Davis FB, Gordinier JK, Davis PJ. 1998. Potentiation by thyroid hormone of human IFN-y-induced HLA-DR expression. J. Immunol. 161:843-49 (Pubitemid 28323549)
24. D'Arezzo S, Incerpi S, Davis FB, Acconcia F, Marino M, et al. 2004. Rapid nongenomic effects of 3,5,3'-triiodo-L-thyronine on the intracellular pH of L-6 myoblasts are mediated by intracellular calcium mobilization and kinase pathways. Endocrinology 145:5694-703 (Pubitemid 39564612)
25. Davis PJ, Davis FB, Cody V. 2005. Membrane receptors mediating thyroid hormone action. Trends Endocrinol. Metab. 16:429-35 (Pubitemid 41506950)
26. Davis PJ, Leonard JL, Davis FB. 2008. Mechanisms of nongenomic actions of thyroid hormone. Front. Neuroendocrinol. 29:211-18 (Pubitemid 351467119)
27. Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK. 2009. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am. J. Physiol. Endocrinol. Metab. 297:E1238-46
28. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. 2008. Metabolic effects of thyroid hormone derivatives. Thyroid 18:239-53 (Pubitemid 351271526)
29. Cody V, Davis PJ, Davis FB. 2007. Molecular modeling of the thyroid hormone interactions with ocv|33 integrin. Steroids 72:166-70
30. Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, et al. 2009. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8:3554-62
31. Modjtahedi H, Essapen S. 2009. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20:851-55
32. Vincenzi B, Zoccoli A, Pantano F, Venditti O, GalluzzoS. 2010. Cetuximab: from bench to bedside. Curr Cancer Drug Targets 10(1):80-95
33. Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, et al. 2009. Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 29:3825-31
34. Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, et al. 2010. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 95(4):1972-80
35. Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, et al. 2010. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20:281-86
36. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. 2008. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11:269-76
37. Yalcin M, Bharali DJ, Dyskin E, Hercbergs AH, Lin HY, et al. 2010. Response of human pancreatic cancer xenografts to nanoparticulate tetraiodothyroacetic acid (tetrac). Submitted
38. Mehta VB, Zhou Y, Radulescu A, Besner GE. 2008. HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors 26:301-15 (Pubitemid 352781843)
39. Shih A, Zhang S, Cao HJ, Tang HY, Davis FB, et al. 2004. Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-aare mediated by 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase II. Endocrinology 145:1708-17 (Pubitemid 38402379)
40. Bidros DS, Liu JK, Vogelbaum MA. 2010. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 6:117-25
41. Coley HM. 2010. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol. Biol. 596:341-58
42. Lu Y, Pang T, Wang J, Xiong D, Ma L, et al. 2008. Down-regulation of P-glycoprotein expression by sustained intracellular acidification in K562/Dox cells. Biochem. Biophys. Res. Commun. 377:441-46
43. MonferranS, SkuliN, Delmas C, Favre G, Bonnet J, etal. 2008. ocv|33 and ov|35 integrins control glioma cell response to ionizing radiation through ILK and RhoB. Int. J. Cancer 123:357-64 (Pubitemid 351842020)
44. Hercbergs A, Davis PJ, Davis FB, Ciesielski MJ, LeithJT. 2009. Radiosensitization of GL261 glioma cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8:2586-91
45. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. 1996. Antagonists of integrin av|33 inhibit retinal neovascularization in a murine model. Lab. Investig. 75:563-73 (Pubitemid 26346806)
46. El Eter E, Rabee H, Alkayali A, Mousa SA. 2007. Role of thyroid hormone analogs in angiogenesis and the development of collaterals in rabbit hind limb ischemia model. J. Thromb. Thrombolysis 5(Suppl. 1):375
47. Safer JD, Crawford TM, HolickMF. 2005. Topical thyroid hormone accelerates wound healing in mice. Endocrinology 146:4425-30 (Pubitemid 41324040)
48. Safer JD, Crawford TM, Holick MF. 2004. A role for thyroid hormone in wound healing through keratin gene expression. Endocrinology 145:2357-61 (Pubitemid 38535065)
49. Nakamura I, Duong LT, Rodan SB, Rodan GA. 2007. Involvement of ocv|33 integrins in osteoclast function. J. Bone Miner. Metab. 25:337-44
50. Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, et al. 2008. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc. Natl. Acad. Sci. USA 105:4289-94 (Pubitemid 351754373)
51. Scarlett A, Parsons MP, Hanson PL, Sidhu KK, Milligan TP, Burrin JM. 2008. Thyroid hormone stimulation of extracellular signal-regulated kinase and cell proliferation in human osteoblast-like cells is initiated at integrin ocv|33.J. Endocrinol. 196:509-17 (Pubitemid 351425506)
52. Bennett JS, Berger BW, Billings PC. 2009. The structure and function of platelet integrins. J. Thromb. Haemost. 7(Suppl. 1):200-5
53. Sheu JJ, Kang JH, Lin HC, Lin HC. 2010. Hyperthyroidism and risk of ischemic stroke in young adults. A 5-year follow-up study. Stroke 41:961-66
54. Yonkers MA, Ribera AB. 2008. Sensory neuron sodium current requires nongenomic actions of thyroid hormone during development. J. Neurophysiol. 100:2719-25
55. Yonkers MA, Ribera AB. 2009. Molecular components underlying nongenomic thyroid hormone signaling in embryonic zebrafish neurons. Neural Dev. 4:20
56. Hiroi Y, Kim HH, Ying H, Furuya F, Huang Z, et al. 2006. Rapid nongenomic actions of thyroid hormone. Proc. Natl. Acad. Sci. USA 103:14104-9 (Pubitemid 44452987)
57. Farwell AP, Dubord-Tomasetti SA, Pietrzykowski AZ, Stachelek SJ, Leonard JL. 2005. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3',5'-triiodothyronine. Brain Res. Dev. Brain Res. 154:121-35 (Pubitemid 40023136)
58. Lin HY, Thacore HR, Davis FB, Davis PJ. 1996. Thyroid hormone analogues potentiate the antiviral action of interferon-yby two mechanisms. J. Cell. Physiol. 167:269-76 (Pubitemid 26146983)
59. Incerpi S, Luly P, De Vito P, Farias RN. 1999. Short-term effects of thyroid hormones on the Na/H an-tiport in L-6 myoblasts: high molecular specificity for 3,3',5-triiodo-L-thyronine. Endocrinology 140:683-89 (Pubitemid 29058201)
60. Davis PJ, Shih A, Lin HY, Martino LJ, Davis FB. 2000. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation ofTR.J. Biol. Chem. 275:38032-39 (Pubitemid 32004926)
61. Shih A, Lin HY, Davis FB, Davis PJ. 2001. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 40:2870-78 (Pubitemid 32198289)
62. Lin HY, Zhang S, West BL, Tang HY, Passaretti T, et al. 2003. Identification of the putative MAP kinase docking site in the thyroid hormone receptor-131 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 42:7571-79 (Pubitemid 36735834)
63. Baumann CT, Maruvada P, Hager GL, Yen PM. 2001. Nuclear cytoplasmic shuttling by thyroid hormone receptors: Multiple protein interactions are required for nuclear retention. J. Biol. Chem. 276:11237-45 (Pubitemid 38089310)
64. Zhu XG, Hanover JA, Hager GL, Cheng SY. 1998. Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera. J. Biol. Chem. 273:27058-63 (Pubitemid 28500409)
65. Chen Y, Chen PL, Chen CF, Sharp ZD, Lee WH. 1999. Thyroid hormone, T3-dependent phosphorylation and translocation of Trip230 from the Golgi complex to the nucleus. Proc. Natl. Acad. Sci. USA 96:4443-48 (Pubitemid 29190355)
66. Caswell PT, Vadrevu S, Norman JC. 2009. Integrins: masters and slaves of endocytic transport. Nat. Rev. Mol. Cell Biol. 10:843-53
67. Caswell PT, Norman JC. 2006. Integrin trafficking and the control of cell migration. Traffic 7:14-21
68. Lin HY, Tang HY, Lin C, Davis FB, Davis PJ. 2007. Thyroid hormone induces nuclear accumulation of monomeric integrin ov and formation of integrin-nucleoprotein complexes. Thyroid 17(Suppl. 1):S129
69. Lee JW, Chu JJ, Ng ML. 2006. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor ocv|33 integrin. J. Biol. Chem. 281:1352-60
70. Somanath PR, Malinin NL, Byzova TV. 2009. Cooperation between integrin ocv|33 and VEGFR2 in angiogenesis. Angiogenesis 12:177-85
71. LossnerD,Abou-Ajram C, Benge A, Reuning U. 2008. Integrin ocv|33 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells. Int. J. Biochem. Cell Biol. 40:2746-61